Inventiva Dividenda 2024

Detalji o dividendama

Razumevanje dividendnih isplata od Inventiva

Dividende od Inventiva su deo profita kompanije koji se distribuira akcionarima. One su ključni indikator finansijskog zdravlja kompanije i atraktivnosti za investitore. Dividende pružaju investitorima stabilan izvor prihoda, pored dobiti koja se možda može ostvariti prodajom akcija po višoj ceni od kupovne.

Poređenje iz godine u godinu

Analiza isplata dividendi od Inventiva tokom godina može istaći profitabilnost i stabilnost kompanije. Konstantno ili rastuće isplate dividendi mogu ukazivati na finansijski zdravu kompaniju sa predvidivim profitom, dok fluktuacije ili smanjenja dividendi mogu signalizirati osnovne finansijske ili operativne izazove.

Uticaj na investicije

Isplate dividendi od Inventiva su suštinski faktor za investitore orijentisane na prihod. Robusna isplata dividendi može povećati privlačnost akcije i pružiti redovni prihod pored potencijalnih kapitalnih dobitaka. Ona može takođe pokazati poverenje kompanije u njene buduće profite i time biti značajan faktor za odlučivanje o investicijama.

Interpretacija fluktuacija dividendi

Promene u dividendama od Inventiva mogu proistići iz promena u profitima kompanije, finansijskoj politici ili strategijama reinvestiranja. Povećanje dividendi često signalizira finansijsku stabilnost, dok smanjenje može ukazivati na potrebu da se sačuva gotovina ili da se profiti reinvestiraju radi podsticanja rasta, pri čemu svaki scenario ima različite posledice za investitore.

Inventiva Aktienanalyse

Шта ради Inventiva?

Inventiva SA is a biopharmaceutical company based in France that specializes in the development of novel therapies for various diseases. The company was founded in 2002 by Pierre Broqua and Frédéric Cren to develop innovative drugs based on research on the human genome. Inventiva's business model is to develop a pipeline of drug candidates and either sell them or bring them into partnerships with other companies. The company has built a broad portfolio of patents and license agreements that allow it to develop a variety of products. Inventiva's research and development focuses on three key areas: fibrosis, oncology, and autoimmune diseases. In these areas, the company has several product candidates in various stages of clinical development. Inventiva's products include Lanifibranor, a drug for the treatment of fatty liver disease, which is currently in Phase III trials. Additionally, the company has several compounds in its oncology pipeline, including IVA337, IVA336, and IVA339, all of which have shown promising results in preclinical studies. In the field of autoimmune diseases, Inventiva is working on a compound called ABBV-157, which is being developed in collaboration with Abbvie. This compound is intended to help reduce inflammation in patients with rheumatoid arthritis and psoriasis. Overall, Inventiva has made significant progress in recent years and has achieved important milestones in the development of its products. The company has also entered into several partnerships with major pharmaceutical and biotech companies to bring its products to market. In 2020, Inventiva took the next important step in its growth strategy by announcing a merger with American company AbbVie. The acquisition is expected to accelerate the development and commercialization of Inventiva's products and provide the company with a strong partner in the international market. However, Inventiva has not limited itself to drug development. The company has also developed a range of services to support other companies in the development of new drugs. These include laboratory services, protein purification and analysis, cell culture, and more, offered through their own contract research organization (CRO) unit. In summary, Inventiva is an emerging company with a strong portfolio of products and services. The company has done excellent work in developing new medical technologies in recent years and is likely to have even more success in the future with the acquisition by AbbVie. Inventiva je jedna od najpopularnijih kompanija na Eulerpool.com.

Često postavljana pitanja o Inventiva akciji

Kolika je dividenda koju isplaćuje Inventiva?

U poslednjih 12 meseci, Inventiva je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Inventiva će verovatno isplatiti dividendu od 0 EUR.

Kolika je dividendna prinosa za Inventiva?

Dividendski prinos od Inventiva trenutno iznosi .

Kada Inventiva isplaćuje dividendu?

Inventiva isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Inventiva?

Inventiva je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Inventiva?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 EUR. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Inventiva?

Inventiva se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Inventiva kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Inventiva od 17. 6. 2024. u iznosu od 0 EUR, morali ste da imate akciju u depou pre Ex-dana 17. 6. 2024..

Kada je Inventiva poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 17. 6. 2024..

Kolika je bila dividenda od Inventiva u godini 2023?

U godini 2023 kompanija Inventiva je isplatila 0 EUR kao dividende.

U kojoj valuti Inventiva isplaćuje dividendu?

Dividende od Inventiva se isplaćuju u EUR.